vs
MARCUS CORP（MCS）与Sotera Health Co（SHC）财务数据对比。点击上方公司名可切换其他公司
Sotera Health Co的季度营收约是MARCUS CORP的1.6倍（$303.4M vs $193.5M），Sotera Health Co同比增速更快（4.6% vs 2.8%），Sotera Health Co自由现金流更多（$52.4M vs $26.4M），过去两年MARCUS CORP的营收复合增速更高（18.2% vs 10.6%）
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
MCS vs SHC — 直观对比
营收规模更大
SHC
是对方的1.6倍
$193.5M
营收增速更快
SHC
高出1.8%
2.8%
自由现金流更多
SHC
多$26.0M
$26.4M
两年增速更快
MCS
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $193.5M | $303.4M |
| 净利润 | — | $34.8M |
| 毛利率 | — | 54.7% |
| 营业利润率 | 0.9% | 23.2% |
| 净利率 | — | 11.5% |
| 营收同比 | 2.8% | 4.6% |
| 净利润同比 | — | 182.8% |
| 每股收益（稀释后） | — | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCSSHC
| Q4 25 | $193.5M | $303.4M | ||
| Q3 25 | $210.2M | $311.3M | ||
| Q2 25 | $206.0M | $294.3M | ||
| Q1 25 | $148.8M | $254.5M | ||
| Q4 24 | $188.3M | $290.2M | ||
| Q3 24 | $232.7M | $285.5M | ||
| Q2 24 | $176.0M | $276.6M | ||
| Q1 24 | $138.5M | $248.2M |
净利润MCSSHC
| Q4 25 | — | $34.8M | ||
| Q3 25 | $16.2M | $48.4M | ||
| Q2 25 | $7.3M | $8.0M | ||
| Q1 25 | $-16.8M | $-13.3M | ||
| Q4 24 | $986.0K | $12.3M | ||
| Q3 24 | $23.3M | $17.0M | ||
| Q2 24 | $-20.2M | $8.8M | ||
| Q1 24 | $-11.9M | $6.3M |
毛利率MCSSHC
| Q4 25 | — | 54.7% | ||
| Q3 25 | — | 57.0% | ||
| Q2 25 | — | 56.6% | ||
| Q1 25 | — | 53.2% | ||
| Q4 24 | — | 56.6% | ||
| Q3 24 | — | 55.4% | ||
| Q2 24 | — | 55.2% | ||
| Q1 24 | — | 51.2% |
营业利润率MCSSHC
| Q4 25 | 0.9% | 23.2% | ||
| Q3 25 | 10.8% | 23.4% | ||
| Q2 25 | 6.3% | 6.4% | ||
| Q1 25 | -13.7% | -5.8% | ||
| Q4 24 | -1.2% | 30.0% | ||
| Q3 24 | 14.1% | 28.2% | ||
| Q2 24 | 1.3% | 27.8% | ||
| Q1 24 | -12.0% | 21.4% |
净利率MCSSHC
| Q4 25 | — | 11.5% | ||
| Q3 25 | 7.7% | 15.5% | ||
| Q2 25 | 3.6% | 2.7% | ||
| Q1 25 | -11.3% | -5.2% | ||
| Q4 24 | 0.5% | 4.2% | ||
| Q3 24 | 10.0% | 6.0% | ||
| Q2 24 | -11.5% | 3.2% | ||
| Q1 24 | -8.6% | 2.5% |
每股收益（稀释后）MCSSHC
| Q4 25 | — | $0.12 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $0.03 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.06 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $344.6M |
| 总债务越低越好 | $159.0M | $2.1B |
| 股东权益账面价值 | $457.4M | $606.0M |
| 总资产 | $1.0B | $3.3B |
| 负债/权益比越低杠杆越低 | 0.35× | 3.53× |
8季度趋势，按日历期对齐
现金及短期投资MCSSHC
| Q4 25 | $23.4M | $344.6M | ||
| Q3 25 | $7.4M | $299.2M | ||
| Q2 25 | $14.9M | $332.4M | ||
| Q1 25 | $11.9M | $304.4M | ||
| Q4 24 | $40.8M | $277.2M | ||
| Q3 24 | $28.4M | $306.7M | ||
| Q2 24 | $32.8M | $246.1M | ||
| Q1 24 | $17.3M | $261.1M |
总债务MCSSHC
| Q4 25 | $159.0M | $2.1B | ||
| Q3 25 | $162.0M | $2.1B | ||
| Q2 25 | $179.9M | $2.2B | ||
| Q1 25 | $198.9M | $2.2B | ||
| Q4 24 | $159.1M | $2.2B | ||
| Q3 24 | $173.1M | $2.2B | ||
| Q2 24 | $175.7M | $2.2B | ||
| Q1 24 | $169.8M | $2.2B |
股东权益MCSSHC
| Q4 25 | $457.4M | $606.0M | ||
| Q3 25 | $454.3M | $550.5M | ||
| Q2 25 | $448.4M | $511.3M | ||
| Q1 25 | $441.8M | $414.1M | ||
| Q4 24 | $464.9M | $404.9M | ||
| Q3 24 | $462.3M | $470.2M | ||
| Q2 24 | $449.4M | $422.8M | ||
| Q1 24 | $459.3M | $429.4M |
总资产MCSSHC
| Q4 25 | $1.0B | $3.3B | ||
| Q3 25 | $1.0B | $3.2B | ||
| Q2 25 | $1.0B | $3.2B | ||
| Q1 25 | $1.0B | $3.1B | ||
| Q4 24 | $1.0B | $3.1B | ||
| Q3 24 | $1.0B | $3.1B | ||
| Q2 24 | $1.1B | $3.1B | ||
| Q1 24 | $1.0B | $3.1B |
负债/权益比MCSSHC
| Q4 25 | 0.35× | 3.53× | ||
| Q3 25 | 0.36× | 3.89× | ||
| Q2 25 | 0.40× | 4.34× | ||
| Q1 25 | 0.45× | 5.36× | ||
| Q4 24 | 0.34× | 5.49× | ||
| Q3 24 | 0.37× | 4.73× | ||
| Q2 24 | 0.39× | 5.26× | ||
| Q1 24 | 0.37× | 5.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.8M | $103.1M |
| 自由现金流经营现金流 - 资本支出 | $26.4M | $52.4M |
| 自由现金流率自由现金流/营收 | 13.6% | 17.3% |
| 资本支出强度资本支出/营收 | 11.6% | 16.7% |
| 现金转化率经营现金流/净利润 | — | 2.96× |
| 过去12个月自由现金流最近4个季度 | $989.0K | $149.2M |
8季度趋势，按日历期对齐
经营现金流MCSSHC
| Q4 25 | $48.8M | $103.1M | ||
| Q3 25 | $39.1M | $71.2M | ||
| Q2 25 | $31.6M | $57.4M | ||
| Q1 25 | $-35.3M | $55.5M | ||
| Q4 24 | $52.6M | $55.7M | ||
| Q3 24 | $30.5M | $97.5M | ||
| Q2 24 | $36.0M | $61.3M | ||
| Q1 24 | $-15.1M | $9.7M |
自由现金流MCSSHC
| Q4 25 | $26.4M | $52.4M | ||
| Q3 25 | $18.2M | $35.0M | ||
| Q2 25 | $14.7M | $26.2M | ||
| Q1 25 | $-58.3M | $35.6M | ||
| Q4 24 | $27.1M | $-10.2M | ||
| Q3 24 | $12.0M | $61.1M | ||
| Q2 24 | $16.1M | $19.4M | ||
| Q1 24 | $-30.5M | $-25.2M |
自由现金流率MCSSHC
| Q4 25 | 13.6% | 17.3% | ||
| Q3 25 | 8.7% | 11.2% | ||
| Q2 25 | 7.1% | 8.9% | ||
| Q1 25 | -39.2% | 14.0% | ||
| Q4 24 | 14.4% | -3.5% | ||
| Q3 24 | 5.2% | 21.4% | ||
| Q2 24 | 9.2% | 7.0% | ||
| Q1 24 | -22.0% | -10.2% |
资本支出强度MCSSHC
| Q4 25 | 11.6% | 16.7% | ||
| Q3 25 | 9.9% | 11.6% | ||
| Q2 25 | 8.2% | 10.6% | ||
| Q1 25 | 15.5% | 7.8% | ||
| Q4 24 | 13.5% | 22.7% | ||
| Q3 24 | 7.9% | 12.7% | ||
| Q2 24 | 11.3% | 15.2% | ||
| Q1 24 | 11.1% | 14.1% |
现金转化率MCSSHC
| Q4 25 | — | 2.96× | ||
| Q3 25 | 2.41× | 1.47× | ||
| Q2 25 | 4.32× | 7.21× | ||
| Q1 25 | — | — | ||
| Q4 24 | 53.31× | 4.52× | ||
| Q3 24 | 1.31× | 5.73× | ||
| Q2 24 | — | 7.00× | ||
| Q1 24 | — | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
